Editas medicine inc EDIT.US 總覽分析

美股醫療保健
(EDIT 無簡報檔)

EDIT 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上

EDIT 近期報酬表現

1.23%

Editas medicine inc

3.56%

同產業平均

1.47%

S&P500

與 EDIT 同產業的標的表現

  • NTLA Intellia therapeutics inc
    價值 4 分趨勢 3 分波段 5 分籌碼 3 分股利 1 分
    查看更多

EDIT 公司資訊

Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

EDIT 股價